Skip to content

Prevention of Capecitabine Induced Hand and Foot Syndrome

A Pilot Study- Prevention of Capecitabine Induced Hand and Foot Syndrome

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01291628
Enrollment
10
Registered
2011-02-08
Start date
2012-01-31
Completion date
2014-01-31
Last updated
2012-01-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Keywords

Capecitabine, Hand and foot syndrome, Socks, Copper, Toxicity

Brief summary

Capecitabine is a common anti cancer drug. One of the most common side effects is a syndrome called hand and foot syndrome which comprises of hands and feet redness, swelling, dryness and painful sores. Quite often the drug dose is reduced to suboptimal level due to this side effect. There is no way to prevent or an effective way to treat this side effect. The investigators aim is to investigate whether wearing socks which contain copper fibers may prevent or alleviate the patient symptoms.

Detailed description

Capecitabine is a common anti cancer drug. One of the most common side effects is a syndrome called hand and foot syndrome which comprises of hands and feet redness, swelling, dryness and painful sores. Quite often the drug dose is reduced to suboptimal level due to this side effect. There is no way to prevent or an effective way to treat this side effect. Our aim is to investigate whether wearing socks which contain copper fibers may prevent or alleviate the patient symptoms. The patients will use socks containing copper-oxide impregnated fibers which are sold in the Pharma stores without physician's prescription.(EPA numbers 8454-2, 8454-3 from April 30 2009). Drug Toxicity and skin reaction will be documented.

Interventions

DEVICEsocks containing copper-oxide fibers

The patients will use a sock which contains copper fibers. The socks are sold in the free market (different Pharma stores) for various purposes such as prevention of diabetic foot. It is a product of Cupron company EPA :84542-2, 84542-3 from April 30 2009.

Sponsors

Rabin Medical Center
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Clinical diagnosis of stage IV cancer - treated with Capecitabine

Exclusion criteria

* Any patient who can not sign an informed consent * Pregnant women

Design outcomes

Primary

MeasureTime frameDescription
skin feet toxicity1 yearwithin the first year from starting Capecitabine use

Countries

Israel

Contacts

Primary ContactRinat Yerusahlmi, MD
rinaty@clalit.org.il972-3-8024
Backup ContactAaron Sulkes, MD
asulkes@clalit.org.il972-3-7940

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026